Read E.V.I.dently Today for current news about health policy and events, among other topics.
E.V.I.dently Today Blog
In a new blog published by Health Affairs, NPC Chief Science Officer and Executive Vice President Robert W. Dubois, MD, PhD, expands on our initial thoughts on the collaboration between the Institute for Clinical Review (ICER) and the U.S. Department of Veterans Affairs (VA) Pharmacy Benefits Management Services.
NPC explores the benefits and challenges with the use of real-world evidence in this first article in a series on this topic.
Appropriate Value Assessment Entails A Broad Perspective Of Impact and A Comprehensive Use of Evidence
NPC Chief Science Officer and Executive Vice President Robert W. Dubois looks at recent publications that highlight the need to consider a societal perspective when assessing value and utilize real-world evidence when appropriate.
NPC President Dan Leonard tackles variable copays in his latest commentary for Chain Drug Review. In it, he considers when variable cost-sharing is less acceptable for patients who require higher-tier formulary medications and highlights recent NPC research examining patient cost-sharing.
A new white paper from Xcenda/AmerisourceBergen and NPC highlights survey findings from payers and providers on what types of evidence are most important to them when it comes to making population coverage decisions for formularies and care pathways.
As real-world evidence (RWE) becomes more broadly used in health care, it’s important to ensure that patients understand what RWE is, determine and address the questions and concerns patients have, and determine when RWE evidence can be trusted to guide patient treatment decisions. The National Health Council held a July 31 roundtable to discuss these issues.